2023
Mouse models for immuno-oncology
Bosenberg M, Liu E, Yu C, Palucka K. Mouse models for immuno-oncology. Trends In Cancer 2023, 9: 578-590. PMID: 37087398, DOI: 10.1016/j.trecan.2023.03.009.Peer-Reviewed Original ResearchMulti-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature
Li Q, Feng T, Zhu T, Zhang W, Qian Y, Zhang H, Zheng X, Li D, Yun X, Zhao J, Li Y, Yu H, Gao M, Qian B. Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature. Journal Of Translational Medicine 2023, 21: 206. PMID: 36941725, PMCID: PMC10026500, DOI: 10.1186/s12967-023-04045-2.Peer-Reviewed Original ResearchConceptsTCGA patientsPositive thyroglobulin antibodiesPapillary thyroid microcarcinomaNew therapeutic hypothesesUnique transcriptomic signaturesImmune-related genesWhole-exome sequencingImmune interventionPeroxidase antibodiesThyroglobulin antibodiesEtiology of cancerRET fusionsThyroid microcarcinomaTCGA cohortBRAF mutationsPatientsDifferent somatic mutationsMulti-omics profilingLarger studyConclusionsOur findingsResultsIn additionExome sequencingTherapeutic hypothesesTranscriptomic signaturesMolecular landscape
2007
A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases
Palacios R, Goni J, Martinez-Forero I, Iranzo J, Sepulcre J, Melero I, Villoslada P. A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases. PLOS ONE 2007, 2: e1222. PMID: 18030350, PMCID: PMC2077806, DOI: 10.1371/journal.pone.0001222.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBayes TheoremCalcium-Binding ProteinsCase-Control StudiesEncephalomyelitis, Autoimmune, ExperimentalEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHumansImmunotherapyIntercellular Signaling Peptides and ProteinsJagged-1 ProteinLymphocyte ActivationMaleMembrane ProteinsMiceMice, Inbred C57BLMultiple SclerosisReverse Transcriptase Polymerase Chain ReactionSerrate-Jagged ProteinsT-LymphocytesConceptsAutoimmune diseasesMultiple sclerosisTherapeutic targetDevelopment of autoimmune diseasesControlling T cell activationExperimental autoimmune encephalomyelitisT cell proliferationTreatment of miceT cell activationTherapy induced changesLevels similar to controlsIn vitro treatmentGene networksGene interactionsTh1 functionTh2 functionTreg functionImmunomodulatory therapyAutoimmune encephalomyelitisSimilar to controlsIngenuity databaseImmune interventionT cellsDisease courseAgonist peptide
1997
Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand
Balashov K, Smith D, Khoury S, Hafler D, Weiner H. Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 599-603. PMID: 9012830, PMCID: PMC19559, DOI: 10.1073/pnas.94.2.599.Peer-Reviewed Original ResearchConceptsIL-12 secretionIFN-gamma secretionMS patientsMultiple sclerosisT cellsIL-12Anti-CD40 ligand antibodyTh1-type immune activationCell-mediated autoimmune diseaseProgressive MS patientsProgressive multiple sclerosisIFN-gamma administrationRelapsing-remitting patientsExacerbation of diseaseInterleukin-12 productionChronic inflammatory diseaseCD40 ligand expressionCentral nervous systemActivated T cellsImmune interventionImmune activationAutoimmune diseasesInterleukin-12Inflammatory diseasesCD40 ligand
1991
Immunotherapy in autoimmune diseases
Miller A, Hafler D, Weiner H. Immunotherapy in autoimmune diseases. Current Opinion In Immunology 1991, 3: 936-940. PMID: 1793539, DOI: 10.1016/s0952-7915(05)80017-2.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunomodulatory therapeutic approachesHuman autoimmune diseasesMajor histocompatibility complex moleculesReceptor gene productsT cell recognitionHistocompatibility complex moleculesImmune interventionImmunological toleranceTherapeutic approachesAnimal modelsDiseaseImmunotherapyTrimolecular complexMolecular basisTolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases
Miller A, Hafler D, Weiner H. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases. The FASEB Journal 1991, 5: 2560-2566. PMID: 1868980, DOI: 10.1096/fasebj.5.11.1868980.Peer-Reviewed Original ResearchConceptsExperimental autoimmune encephalomyelitisAutoimmune encephalomyelitisAutoimmune diseasesAnimal model experimental autoimmune encephalomyelitisModel experimental autoimmune encephalomyelitisHuman disease multiple sclerosisSpecific immune interventionAutoimmune T cellsHuman autoimmune diseasesNormal immune systemDisease multiple sclerosisMajor histocompatibility complexImmunospecific therapyTrimolecular complexImmune interventionSelective immunotherapyMultiple sclerosisT cellsImmune functionNonspecific modulationImmune systemAntigen recognitionHistocompatibility complexSuppressor mechanismDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply